Prenatal Vaccination With RSV Prefusion F Does Not Increase Risk for Preterm Birth
By Elana Gotkine HealthDay Reporter
FRIDAY, July 12, 2024 -- Prenatal vaccination with a nonadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) protein subunit vaccine is not associated with an increased risk for preterm birth (PTB), according to a study published online July 8 in JAMA Network Open.
In a retrospective observational cohort study, Moeun Son, M.D., from the Weill Cornell Medical College in New York City, and colleagues examined the association between prenatal RSV vaccination status and perinatal outcomes among patients who delivered during the vaccination season. Data were included for 2,973 pregnant individuals, 34.5 percent of whom received prenatal RSVpreF vaccination.
The researchers found that 60 patients who had evidence of prenatal vaccination experienced PTB compared with 131 of those without evidence of prenatal vaccination (5.9 versus 6.7 percent). There was no association seen for prenatal vaccination with an increased risk for PTB after adjustment for potential confounding variables and addressing immortal time bias. Pregnancy and neonatal outcomes did not differ significantly based on vaccination status, but an increased risk for hypertensive disorders of pregnancy was seen in the time-dependent model.
"In the main analyses, there were no significant differences in maternal or perinatal outcomes between patients who had electronic health record evidence of prenatal RSVpreF vaccination and those who did not," the authors write.
Two authors disclosed ties to Pfizer, the manufacturer of the RSVpreF vaccine.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...
Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and...
Live Zoster Vaccination Linked to Lower Risk for Cardiovascular Events
THURSDAY, May 8, 2025 -- Live zoster vaccination is associated with a lower risk for overall cardiovascular events when compared with no vaccination, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.